title: [Methods to obtain platelet-rich plasma and osteoinductive therapeutic use].
abstract: BACKGROUND
  Platelet-Rich Plasma (PRP) is autologous plasma with higher concentration of platelet than basal level, because of an extracting and concentration process. PRP therapeutical use, as osteinductor role, is a controversial issue, due to there are no clinical studies with rigorous design and no firm conclusions can be drawn regarding its uses. Propose: To provide information about methods to obtain PRP, legal considerations about its extraction and use, molecular mechanism of action, as well as available evidence about security and tolerance.
  
  
  RESULTS
  PRP can be obtained by manual procedures (opened technique) or disposable kits (closed technique), the latter being medical devices classified as type IIa. AEMPS considers PRP as a drug, establishing some minimum requirements to guarantee safety, traceability, pharmacovigilance and information. PRP provides ideal qualities to play a powerful osteoinductor role to speed up fracture healing or to produce an efficiently and quickly osseointegration of different bone implants, due to the high growth factors content. Infiltration tolerance is generally good, however, it has to be taken into account its great angiogenical potential.
  
  
  CONCLUSIONS
  In view of its production and application characteristics, PRP is considered as a drug on restricted medical prescription by the AEMPS, so pharmacy department must, at least, supervise its management and handling.
authors.affiliation: Jefe del Servicio de Farmacia. Hospital Universitario Infanta Cristina. Parla. Madrid. Miembro del Grupo de Productos Sanitarios de la Sociedad Española de Farmacia Hospitalaria (SEFH).. rmorenod@salud.madrid.org.
authors.forename: Raquel
authors.initials: R
authors.lastname: Moreno
authors.affiliation: Jefe de Servicio Farmacia. Hospital Intermutual de Levante. Valencia. Miembro del Grupo de Productos Sanitarios de la Sociedad Española de Farmacia Hospitalaria (SEFH).. rmorenod@salud.madrid.org.
authors.forename: Marisa
authors.initials: M
authors.lastname: Gaspar Carreño
authors.affiliation: Responsable Dpto. de Compras Hospitales Pascual. Cádiz. Miembro del Grupo de Productos Sanitarios de la Sociedad Española de Farmacia Hospitalaria (SEFH).. rmorenod@salud.madrid.org.
authors.forename: José
authors.initials: J
authors.lastname: Jiménez Torres
authors.affiliation: Facultativo Especialista de Área. Hospital Los Arcos Mar Menor. Murcia. Miembro del Grupo de Productos Sanitarios de la Sociedad Española de Farmacia Hospitalaria (SEFH).. rmorenod@salud.madrid.org.
authors.forename: José María
authors.initials: JM
authors.lastname: Alonso Herreros
authors.affiliation: Especialista en Farmacia Hospitalaria. Departamento de Productos Sanitarios. Agencia Española de Medicamentos y Productos Sanitarios. Miembro del Grupo de Farmacotecnia de la SEFH. España.. rmorenod@salud.madrid.org.
authors.forename: Ana
authors.initials: A
authors.lastname: Villimar
authors.affiliation: Especialista en Farmacia Hospitalaria. Complejo Hospitalario de Toledo. Toledo. Miembro del Grupo de Productos Sanitarios de la Sociedad Española de Farmacia Hospitalaria (SEFH).. piedadls@gmail.com.
authors.forename: Piedad
authors.initials: P
authors.lastname: López Sánchez
mesh_terms: D011307:Drug Prescriptions; D017102:Fracture Healing / Q000187:drug effects*; D050723:Fractures, Bone / Q000188:drug therapy*; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects*; D010607:Pharmacy Service, Hospital; D053657:Platelet-Rich Plasma